Early Prediction of Response Focused on Tumor Markers in Atezolizumab plus Bevacizumab Therapy for Hepatocellular Carcinoma
Despite the promising efficacy of atezolizumab plus bevacizumab (atezo/bev), some patients with unresectable hepatocellular carcinoma (HCC) experience disease progression. This retrospective study, which included 154 patients, aimed to evaluate predictors of treatment efficacy of atezo/bev for unres...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/11/2927 |
| _version_ | 1797597797040521216 |
|---|---|
| author | Norikazu Tanabe Issei Saeki Yuki Aibe Takashi Matsuda Tadasuke Hanazono Maiko Nishi Isao Hidaka Shinya Kuwashiro Shogo Shiratsuki Keiji Matsuura Maho Egusa Natsuko Nishiyama Tsuyoshi Fujioka Daiki Kawamoto Ryo Sasaki Tatsuro Nishimura Takashi Oono Takuro Hisanaga Toshihiko Matsumoto Tsuyoshi Ishikawa Takahiro Yamasaki Taro Takami |
| author_facet | Norikazu Tanabe Issei Saeki Yuki Aibe Takashi Matsuda Tadasuke Hanazono Maiko Nishi Isao Hidaka Shinya Kuwashiro Shogo Shiratsuki Keiji Matsuura Maho Egusa Natsuko Nishiyama Tsuyoshi Fujioka Daiki Kawamoto Ryo Sasaki Tatsuro Nishimura Takashi Oono Takuro Hisanaga Toshihiko Matsumoto Tsuyoshi Ishikawa Takahiro Yamasaki Taro Takami |
| author_sort | Norikazu Tanabe |
| collection | DOAJ |
| description | Despite the promising efficacy of atezolizumab plus bevacizumab (atezo/bev), some patients with unresectable hepatocellular carcinoma (HCC) experience disease progression. This retrospective study, which included 154 patients, aimed to evaluate predictors of treatment efficacy of atezo/bev for unresectable HCC. Factors associated with treatment response were examined, focusing on tumor markers. In the high-alpha-fetoprotein (AFP) group (baseline AFP ≥ 20 ng/mL), a decrease in AFP level > 30% was an independent predictor of objective response (odds ratio, 5.517; <i>p</i> = 0.0032). In the low-AFP group (baseline AFP < 20 ng/mL), baseline des-gamma-carboxy prothrombin (DCP) level < 40 mAU/mL was an independent predictor of objective response (odds ratio, 3.978; <i>p</i> = 0.0206). The independent predictors of early progressive disease were an increase in AFP level ≥ 30% at 3 weeks (odds ratio, 4.077; <i>p</i> = 0.0264) and the presence of extrahepatic spread (odds ratio, 3.682; <i>p</i> = 0.0337) in the high-AFP group and up-to-seven criteria, OUT (odds ratio, 15.756; <i>p</i> = 0.0257) in the low-AFP group. In atezo/bev therapy, focusing on early AFP changes, baseline DCP, and tumor burden of up-to-seven criteria are useful in predicting response to treatment. |
| first_indexed | 2024-03-11T03:10:32Z |
| format | Article |
| id | doaj.art-5d70ddba89204a0785ea8b0602326eeb |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T03:10:32Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-5d70ddba89204a0785ea8b0602326eeb2023-11-18T07:38:25ZengMDPI AGCancers2072-66942023-05-011511292710.3390/cancers15112927Early Prediction of Response Focused on Tumor Markers in Atezolizumab plus Bevacizumab Therapy for Hepatocellular CarcinomaNorikazu Tanabe0Issei Saeki1Yuki Aibe2Takashi Matsuda3Tadasuke Hanazono4Maiko Nishi5Isao Hidaka6Shinya Kuwashiro7Shogo Shiratsuki8Keiji Matsuura9Maho Egusa10Natsuko Nishiyama11Tsuyoshi Fujioka12Daiki Kawamoto13Ryo Sasaki14Tatsuro Nishimura15Takashi Oono16Takuro Hisanaga17Toshihiko Matsumoto18Tsuyoshi Ishikawa19Takahiro Yamasaki20Taro Takami21Division of Laboratory, Yamaguchi University Hospital, Ube 755-8505, Yamaguchi, JapanDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube 755-8505, Yamaguchi, JapanYamaguchi Clinical Research Group—Hepatology (YCR-H), Ube 755-8505, Yamaguchi, JapanYamaguchi Clinical Research Group—Hepatology (YCR-H), Ube 755-8505, Yamaguchi, JapanYamaguchi Clinical Research Group—Hepatology (YCR-H), Ube 755-8505, Yamaguchi, JapanYamaguchi Clinical Research Group—Hepatology (YCR-H), Ube 755-8505, Yamaguchi, JapanYamaguchi Clinical Research Group—Hepatology (YCR-H), Ube 755-8505, Yamaguchi, JapanYamaguchi Clinical Research Group—Hepatology (YCR-H), Ube 755-8505, Yamaguchi, JapanYamaguchi Clinical Research Group—Hepatology (YCR-H), Ube 755-8505, Yamaguchi, JapanYamaguchi Clinical Research Group—Hepatology (YCR-H), Ube 755-8505, Yamaguchi, JapanDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube 755-8505, Yamaguchi, JapanDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube 755-8505, Yamaguchi, JapanDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube 755-8505, Yamaguchi, JapanDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube 755-8505, Yamaguchi, JapanDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube 755-8505, Yamaguchi, JapanDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube 755-8505, Yamaguchi, JapanDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube 755-8505, Yamaguchi, JapanDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube 755-8505, Yamaguchi, JapanDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube 755-8505, Yamaguchi, JapanDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube 755-8505, Yamaguchi, JapanDivision of Laboratory, Yamaguchi University Hospital, Ube 755-8505, Yamaguchi, JapanDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube 755-8505, Yamaguchi, JapanDespite the promising efficacy of atezolizumab plus bevacizumab (atezo/bev), some patients with unresectable hepatocellular carcinoma (HCC) experience disease progression. This retrospective study, which included 154 patients, aimed to evaluate predictors of treatment efficacy of atezo/bev for unresectable HCC. Factors associated with treatment response were examined, focusing on tumor markers. In the high-alpha-fetoprotein (AFP) group (baseline AFP ≥ 20 ng/mL), a decrease in AFP level > 30% was an independent predictor of objective response (odds ratio, 5.517; <i>p</i> = 0.0032). In the low-AFP group (baseline AFP < 20 ng/mL), baseline des-gamma-carboxy prothrombin (DCP) level < 40 mAU/mL was an independent predictor of objective response (odds ratio, 3.978; <i>p</i> = 0.0206). The independent predictors of early progressive disease were an increase in AFP level ≥ 30% at 3 weeks (odds ratio, 4.077; <i>p</i> = 0.0264) and the presence of extrahepatic spread (odds ratio, 3.682; <i>p</i> = 0.0337) in the high-AFP group and up-to-seven criteria, OUT (odds ratio, 15.756; <i>p</i> = 0.0257) in the low-AFP group. In atezo/bev therapy, focusing on early AFP changes, baseline DCP, and tumor burden of up-to-seven criteria are useful in predicting response to treatment.https://www.mdpi.com/2072-6694/15/11/2927hepatocellular carcinomaatezolizumabbevacizumabalpha-fetoproteindes-gamma-carboxy prothrombinimmune checkpoint inhibitor |
| spellingShingle | Norikazu Tanabe Issei Saeki Yuki Aibe Takashi Matsuda Tadasuke Hanazono Maiko Nishi Isao Hidaka Shinya Kuwashiro Shogo Shiratsuki Keiji Matsuura Maho Egusa Natsuko Nishiyama Tsuyoshi Fujioka Daiki Kawamoto Ryo Sasaki Tatsuro Nishimura Takashi Oono Takuro Hisanaga Toshihiko Matsumoto Tsuyoshi Ishikawa Takahiro Yamasaki Taro Takami Early Prediction of Response Focused on Tumor Markers in Atezolizumab plus Bevacizumab Therapy for Hepatocellular Carcinoma Cancers hepatocellular carcinoma atezolizumab bevacizumab alpha-fetoprotein des-gamma-carboxy prothrombin immune checkpoint inhibitor |
| title | Early Prediction of Response Focused on Tumor Markers in Atezolizumab plus Bevacizumab Therapy for Hepatocellular Carcinoma |
| title_full | Early Prediction of Response Focused on Tumor Markers in Atezolizumab plus Bevacizumab Therapy for Hepatocellular Carcinoma |
| title_fullStr | Early Prediction of Response Focused on Tumor Markers in Atezolizumab plus Bevacizumab Therapy for Hepatocellular Carcinoma |
| title_full_unstemmed | Early Prediction of Response Focused on Tumor Markers in Atezolizumab plus Bevacizumab Therapy for Hepatocellular Carcinoma |
| title_short | Early Prediction of Response Focused on Tumor Markers in Atezolizumab plus Bevacizumab Therapy for Hepatocellular Carcinoma |
| title_sort | early prediction of response focused on tumor markers in atezolizumab plus bevacizumab therapy for hepatocellular carcinoma |
| topic | hepatocellular carcinoma atezolizumab bevacizumab alpha-fetoprotein des-gamma-carboxy prothrombin immune checkpoint inhibitor |
| url | https://www.mdpi.com/2072-6694/15/11/2927 |
| work_keys_str_mv | AT norikazutanabe earlypredictionofresponsefocusedontumormarkersinatezolizumabplusbevacizumabtherapyforhepatocellularcarcinoma AT isseisaeki earlypredictionofresponsefocusedontumormarkersinatezolizumabplusbevacizumabtherapyforhepatocellularcarcinoma AT yukiaibe earlypredictionofresponsefocusedontumormarkersinatezolizumabplusbevacizumabtherapyforhepatocellularcarcinoma AT takashimatsuda earlypredictionofresponsefocusedontumormarkersinatezolizumabplusbevacizumabtherapyforhepatocellularcarcinoma AT tadasukehanazono earlypredictionofresponsefocusedontumormarkersinatezolizumabplusbevacizumabtherapyforhepatocellularcarcinoma AT maikonishi earlypredictionofresponsefocusedontumormarkersinatezolizumabplusbevacizumabtherapyforhepatocellularcarcinoma AT isaohidaka earlypredictionofresponsefocusedontumormarkersinatezolizumabplusbevacizumabtherapyforhepatocellularcarcinoma AT shinyakuwashiro earlypredictionofresponsefocusedontumormarkersinatezolizumabplusbevacizumabtherapyforhepatocellularcarcinoma AT shogoshiratsuki earlypredictionofresponsefocusedontumormarkersinatezolizumabplusbevacizumabtherapyforhepatocellularcarcinoma AT keijimatsuura earlypredictionofresponsefocusedontumormarkersinatezolizumabplusbevacizumabtherapyforhepatocellularcarcinoma AT mahoegusa earlypredictionofresponsefocusedontumormarkersinatezolizumabplusbevacizumabtherapyforhepatocellularcarcinoma AT natsukonishiyama earlypredictionofresponsefocusedontumormarkersinatezolizumabplusbevacizumabtherapyforhepatocellularcarcinoma AT tsuyoshifujioka earlypredictionofresponsefocusedontumormarkersinatezolizumabplusbevacizumabtherapyforhepatocellularcarcinoma AT daikikawamoto earlypredictionofresponsefocusedontumormarkersinatezolizumabplusbevacizumabtherapyforhepatocellularcarcinoma AT ryosasaki earlypredictionofresponsefocusedontumormarkersinatezolizumabplusbevacizumabtherapyforhepatocellularcarcinoma AT tatsuronishimura earlypredictionofresponsefocusedontumormarkersinatezolizumabplusbevacizumabtherapyforhepatocellularcarcinoma AT takashioono earlypredictionofresponsefocusedontumormarkersinatezolizumabplusbevacizumabtherapyforhepatocellularcarcinoma AT takurohisanaga earlypredictionofresponsefocusedontumormarkersinatezolizumabplusbevacizumabtherapyforhepatocellularcarcinoma AT toshihikomatsumoto earlypredictionofresponsefocusedontumormarkersinatezolizumabplusbevacizumabtherapyforhepatocellularcarcinoma AT tsuyoshiishikawa earlypredictionofresponsefocusedontumormarkersinatezolizumabplusbevacizumabtherapyforhepatocellularcarcinoma AT takahiroyamasaki earlypredictionofresponsefocusedontumormarkersinatezolizumabplusbevacizumabtherapyforhepatocellularcarcinoma AT tarotakami earlypredictionofresponsefocusedontumormarkersinatezolizumabplusbevacizumabtherapyforhepatocellularcarcinoma |